Now I have everything I need. Let me compile the full, comprehensive, well-illustrated pharmacology guide on heart failure drugs.
Drugs for Heart Failure - Complete Pharmacology Guide ๐ซ
First, Understand the Problem: Why Does Heart Failure Progress?
When the heart fails, two major compensation systems kick in - and both ultimately make things worse:
Compensation Flowchart (from Katzung's Pharmacology):
The key insight: โ Cardiac output โ baroreceptors fire less โ โ Sympathetic discharge + โ Renin โ โ Angiotensin II โ โ Preload, โ Afterload, Remodeling โ further โ CO. This is the vicious cycle:
Every drug class we use targets one or more links in this cycle.
The Big Picture: What Are We Treating?
HEART FAILURE (HFrEF: EF <40%)
|
โโโ SYMPTOMS (dyspnea, edema, fatigue)
| โ Treat with: Diuretics, Nitrates
|
โโโ NEUROHUMORAL ACTIVATION (RAAS + SNS going haywire)
| โ Treat with: ACEi / ARB / ARNI, Beta-blockers, MRA
|
โโโ PUMP FAILURE (โ contractility)
| โ Treat with: Digoxin, Dobutamine (acute), Levosimendan
|
โโโ RENAL SODIUM RETENTION
| โ Treat with: SGLT2 inhibitors, Diuretics
|
โโโ FAST HEART RATE (โ Oโ demand, poor filling)
โ Treat with: Beta-blockers, Ivabradine
Drug Class 1: DIURETICS
"The Plumbers" - Remove the Excess Volume
Types used in HF:
| Drug | Type | Site of Action | Potency |
|---|
| Furosemide | Loop diuretic | Thick ascending limb of loop of Henle - blocks NaCl/KCl reabsorption | โญโญโญ HIGH |
| Spironolactone / Eplerenone | MRA (K+-sparing) | Collecting duct - blocks aldosterone | โญโญ MED |
| Hydrochlorothiazide | Thiazide | Distal convoluted tubule | โญ LOW |
| SGLT2 inhibitors (Empagliflozin, Dapagliflozin) | Glucosuric diuretic | Proximal tubule | โญโญ + extra HF benefits |
Mechanism flowchart:
FUROSEMIDE
โ
Blocks Naโบ/Kโบ/2Clโป cotransporter in thick ascending LOH
โ
โ NaCl reabsorption โ โ urine output
โ
โ Circulating volume
โ
โ Venous return (preload) โ Pulmonary/peripheral edema
โ โ
โ Cardiac work โ Dyspnea / orthopnea โ SYMPTOM RELIEF
Key toxicities to remember:
- Furosemide: Hypokalemia (dangerous with digoxin!), hypovolemia, ototoxicity, sulfonamide allergy
- Spironolactone: Hyperkalemia, gynecomastia (use eplerenone to avoid this)
- SGLT2i: Genital mycotic infections, euglycemic DKA (type 1 DM contraindicated)
Drug Class 2: ACE Inhibitors (ACEi)
"The Firefighters of the RAAS" - Block the Root Cause
Prototype drugs: Enalapril, Lisinopril, Captopril, Ramipril
Mechanism:
Angiotensinogen
โ Renin
Angiotensin I
โ ACE โ โโโโโโโโโโ BLOCKED BY ACEi
Angiotensin II Bradykinin degradation โ ALSO BLOCKED
| โ
โ โ โ โ Bradykinin (โ COUGH side effect)
Vasoconstriction
Aldosterone release
Sympathetic activation
Cardiac remodeling
RESULT: โ Preload + โ Afterload + โ Remodeling
Clinical benefits:
- โ Mortality in all stages of HFrEF (Class I indication)
- Slows ventricular dilation in asymptomatic LV dysfunction
- Benefits ALL subsets of HF patients
Side effects: Dry cough (10-15% - due to โ bradykinin), angioedema (rare), hyperkalemia, renal impairment, teratogenicity
"ACE inhibitors are superior to placebo AND to vasodilators and must be considered along with diuretics as first-line therapy for chronic heart failure." - Katzung's Pharmacology
Drug Class 3: ARBs (Angiotensin Receptor Blockers)
"Same Benefit, No Cough"
Prototype drugs: Losartan, Valsartan, Candesartan
Mechanism:
Angiotensin II is still formed...
โ
ATโ receptor โ โโโโโ BLOCKED BY ARB
Cannot cause vasoconstriction, aldosterone release, or remodeling
BONUS: No bradykinin buildup โ NO COUGH
Use in HF:
- Reserved for patients who CANNOT tolerate ACEi (cough, angioedema)
- Produce similar hemodynamic benefits to ACEi
- Do NOT combine ARB + ACEi (double RAAS blockade = hyperkalemia + renal failure risk)
Drug Class 4: ARNI (Angiotensin Receptor Neprilysin Inhibitor)
"The Upgrade" - Sacubitril/Valsartan (Entresto)
This is the newest star of HFrEF treatment - outperforms ACEi/ARB alone.
Mechanism:
Sacubitril Valsartan
โ โ
Inhibits Neprilysin Blocks ATโ receptor
โ
Prevents breakdown of:
- BNP, ANP (natriuretic peptides)
- Bradykinin
โ
โ Natriuresis โ RAAS activation
โ Vasodilation โ Remodeling
โ Diuresis
โ โ โ โ
โโ Preload + Afterload
โโ Symptoms AND NT-proBNP (biomarker)
โโ HF hospitalizations + MORTALITY vs Enalapril (PARADIGM-HF trial)
Rule: NEVER use ARNI + ACEi together (risk of severe angioedema). Washout period of 36 hours required when switching from ACEi.
Drug Class 5: Beta-Blockers
"The Counter-intuitive Lifesavers"
Approved drugs in HF (not a class effect - only these three/four work):
- Carvedilol (non-selective ฮฒ + ฮฑโ blocker)
- Bisoprolol (selective ฮฒโ blocker)
- Metoprolol succinate (selective ฮฒโ, extended release)
- Nebivolol (ฮฒโ + NO-releasing)
Why they work (the paradox):
Short-term: โ CO, โ HR, โ contractility โ patient may feel worse initially
โ
Long-term (months of therapy):
- โ ฮฒโ receptor upregulation (were downregulated by excess catecholamines)
- โ Pathological remodeling
- โ Apoptosis (cell death)
- โ Arrhythmias (major cause of death in HF)
- โ Tachycardia โ better diastolic filling
โ
โ EF (slight but real)
โ Mortality 30-35% (large RCTs: MERIT-HF, COPERNICUS)
Critical rule: START LOW, GO SLOW - never initiate during acute decompensation. Wait for euvolemia.
Drug Class 6: Aldosterone Antagonists / MRA
"The Potassium-Sparing Mortality Reducers"
Drugs: Spironolactone, Eplerenone
Mechanism (beyond just diuresis):
In HF, Aldosterone is CHRONICALLY elevated
โ
Myocardial fibrosis
Endothelial dysfunction
SNS activation
Hypokalemia/hypomagnesemia
MRAs block these DIRECTLY at receptor level (not just kidneys!)
โ
โ Cardiac fibrosis
โ Remodeling
โ Sudden cardiac death
โ Overall mortality (RALES trial: 30% reduction)
When to use: All moderate-severe HFrEF (NYHA II-IV) with CrCl >30 and K+ <5.0
Avoid if: K+ >5.0, GFR <30, or on both ACEi + ARB already
Drug Class 7: SGLT2 Inhibitors
"The Game-Changers from Diabetes"
Drugs: Empagliflozin (EMPA-REG), Dapagliflozin (DAPA-HF), Canagliflozin
Mechanism (multi-pronged!):
SGLT2 inhibition in proximal tubule
โ
โ Urinary glucose + sodium excretion
โ
โ Volume overload (diuretic effect) โ Cardiac Naโบ/Hโบ exchanger activity
โ Preload โ Intracellular Ca2+ overload
โ Afterload โ Mitochondrial dysfunction
โ โ
โ Symptoms โ Cardiomyocyte death
โ โ
โ HF Hospitalizations + โ CV Death
(works in BOTH HFrEF AND HFpEF!)
The big news: Works even in patients WITHOUT diabetes. Now part of standard "quadruple therapy" for HFrEF.
Drug Class 8: Digoxin (Cardiac Glycosides)
"The Old Workhorse"
Prototype: Digoxin (from Digitalis lanata leaf)
Dual mechanism:
Mechanism 1: Naโบ/Kโบ-ATPase inhibition
โ
โ Intracellular Naโบ
โ
Naโบ/Caยฒโบ exchanger reverses
โ
โ Intracellular Caยฒโบ
โ
โ CONTRACTILITY (positive inotrope)
Mechanism 2: โ Vagal tone (parasympathomimetic)
โ
โ Heart rate
โ AV node conduction velocity
โ Controls ventricular rate in Atrial Fibrillation
Narrow therapeutic index - MEMORIZE toxic levels:
- Therapeutic: 0.5-0.8 ng/mL (HF) / up to 2.0 ng/mL (AF)
- Toxic: >2.0 ng/mL
Toxicity signs (in order of severity):
- GI: Nausea, vomiting, anorexia (earliest)
- Visual: Yellow-green halos, blurred vision
- Cardiac: Bradycardia, heart block, PVCs, ventricular arrhythmias (LETHAL)
Precipitants of toxicity: Hypokalemia (competitive with K+ at pump), hypomagnesemia, renal failure, hypothyroidism, quinidine (doubles digoxin level)
Current use: Mainly for HF + AF symptom control. Does NOT reduce mortality.
Drug Class 9: Vasodilators
"Opening the Pipes"
Isosorbide dinitrate + Hydralazine (BiDil):
Hydralazine (arteriolar dilator) Isosorbide Dinitrate (venodilator)
โ โ
โ SVR โ โ Afterload โ Venous return โ โ Preload
โ Forward cardiac output โ Pulmonary edema
โ โ
COMBINED BENEFIT
Proven mortality reduction in BLACK patients
(A-HeFT trial; BiDil: first race-specific drug approval)
Nitroprusside + Nitroglycerin (IV - used in ACUTE HF only):
- Nitroprusside: Balanced vasodilator (arterial + venous), very potent, requires ICU monitoring
- Nitroglycerin: Mainly venodilator โ reduces pulmonary congestion rapidly
Drug Class 10: Ivabradine
"The Selective Heart Rate Reducer"
Mechanism:
Blocks the If ("funny") current (HCN channels) in SA node
โ
โ Spontaneous depolarization rate
โ
โ Heart rate (WITHOUT reducing contractility)
โ
Better diastolic filling time
โ
โ CO + โ myocardial Oโ demand
Use: NYHA II-III HFrEF on maximally tolerated beta-blocker dose, with HR still >70 bpm, in normal sinus rhythm (SHIFT trial: reduced HF hospitalizations)
Drug Class 11: Positive Inotropes (Acute HF Only)
"Emergency Pumpers - Short-term Use Only"
Dobutamine (ฮฒโ agonist):
ฮฒโ receptor โ โ cAMP โ โ Caยฒโบ โ โ Contractility
Used IV for acute decompensated HF with hypotension
CAUTION: โ Mortality with chronic use (pro-arrhythmic)
Milrinone (PDE-3 inhibitor):
Inhibits PDE-3 โ โ cAMP (same downstream as dobutamine)
+ Vasodilation (reduces afterload)
Used IV in acute HF / pre-transplant bridging
CAUTION: Pro-arrhythmic, โ mortality long-term
Levosimendan (Calcium sensitizer):
Does NOT increase intracellular Caยฒโบ
Instead: Sensitizes troponin C to existing Caยฒโบ
โ Oโ demand while โ contractile force
Also: Opens K-ATP channels โ vasodilation
Non-inferior to dobutamine (SURVIVE trial), approved in Europe
The Complete Treatment Algorithm (AHA/ACC 2017 Guidelines)
Reading the algorithm:
- Step 1: Establish HFrEF diagnosis, assess volume, start GDMT (Guideline-Directed Medical Therapy)
- Step 2: Base drug: ACEi OR ARB + Beta-blocker + Diuretics as needed
- Step 3: Add based on clinical scenario:
- NYHA II-IV + normal K+ โ Add MRA (spironolactone/eplerenone)
- NYHA II-III, tolerable BP โ Upgrade to ARNI (sacubitril/valsartan, discontinue ACEi/ARB)
- NYHA III-IV in Black patients โ Add ISDN + Hydralazine
- LVEF โค35% + expected >1 yr survival โ ICD (implantable cardioverter-defibrillator)
- LBBB + QRS >150ms โ CRT (cardiac resynchronization therapy)
- HR >70 on max beta-blocker โ Add Ivabradine
- Step 4: Reassess symptoms
- Step 5 (Stage D): Palliative care / Heart transplantation / LVAD
Drug Treatments for HFpEF (Preserved EF, EF >50%)
This is the harder-to-treat type. The pathophysiology (from Goodman & Gilman):
HFpEF treatment summary:
| Drug | Role in HFpEF |
|---|
| Diuretics | Yes - symptom relief (use cautiously, over-diuresis worsens CO) |
| ACEi/ARB | May help โ LVH (less proven for mortality) |
| Beta-blockers | โ HR โ better diastolic filling time |
| MRA | Modest benefit |
| SGLT2 inhibitors | Proven benefit - the only drug class with RCT-proven HFpEF benefit (EMPEROR-Preserved trial) |
| Calcium channel blockers | Verapamil/diltiazem - โ HR, โ BP (more useful here than HFrEF) |
| Positive inotropes | NOT recommended |
| Digoxin | Little to no role |
"Quadruple Therapy" - The Modern Standard for HFrEF
Current guidelines (2022 ACC/AHA) recommend ALL FOUR of these simultaneously for HFrEF:
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ QUADRUPLE THERAPY FOR HFrEF โ
โ โ
โ 1. ARNI (sacubitril/valsartan) โ
โ OR ACEi / ARB if ARNI not tolerated โ
โ โ
โ 2. Beta-blocker โ
โ (bisoprolol / carvedilol / metoprolol)โ
โ โ
โ 3. MRA โ
โ (spironolactone / eplerenone) โ
โ โ
โ 4. SGLT2 inhibitor โ
โ (empagliflozin / dapagliflozin) โ
โ โ
โ + Diuretic (furosemide) for symptoms โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
Each pillar independently reduces mortality. Together they reduce the risk of HF hospitalization and death by ~60-70%.
Quick Reference Summary Table
| Drug Class | Key Drugs | Main Mechanism | Effect on Preload | Effect on Afterload | Effect on Contractility | Reduces Mortality? |
|---|
| Loop Diuretics | Furosemide | Block LOH NaCl transport | โโ | โ | None | No (symptoms only) |
| SGLT2i | Empagliflozin | Natriuresis + direct cardiac effects | โ | โ | None | โ
Yes |
| ACEi | Enalapril | Block ACE โ โ Ang II | โ | โโ | None | โ
Yes |
| ARB | Losartan | Block ATโ receptor | โ | โโ | None | โ
Yes |
| ARNI | Sacubitril/Valsartan | Block ATโ + โ natriuretics | โโ | โโ | None | โ
Yes (best) |
| Beta-blocker | Carvedilol, Bisoprolol | Block ฮฒโ receptors | None | โ (mild) | โ short-term / โ long-term | โ
Yes |
| MRA | Spironolactone | Block aldosterone receptor | โ | โ (mild) | None | โ
Yes |
| Digoxin | Digoxin | Na/K-ATPase inhibitor | โ (mild) | None | โโ | No (symptoms/AF rate control) |
| Nitrates | ISDN, Nitroglycerin | โ NO โ venodilation | โโ | None | None | In combo (Black patients) |
| Hydralazine | Hydralazine | Direct arteriodilation | None | โโ | None | In combo (Black patients) |
| Dobutamine | Dobutamine | ฮฒโ agonist | None | โ (mild) | โโ | No (acute use only) |
| Ivabradine | Ivabradine | Block If current in SA node | None | None | None | Reduces hospitalizations |
| Levosimendan | Levosimendan | Caยฒโบ sensitizer | โ | โ | โ (efficiency) | Acute HF only |
Key "One-Liners" to Remember for Exams
- ACEi = First-line in HFrEF (superior to vasodilators alone; benefit in all stages)
- ARNI > ACEi in tolerating patients (PARADIGM-HF trial)
- Beta-blockers START acutely worsen but chronically save lives - never initiate in decompensation
- MRA toxicity = Hyperkalemia - check K+ and creatinine before starting
- Digoxin only reduces symptoms + controls AF rate - does NOT reduce mortality
- SGLT2i work in HF without diabetes - mechanism beyond glucose control
- BiDil (ISDN + Hydralazine) = proven only in Black patients (A-HeFT trial)
- Ivabradine = only useful in sinus rhythm (no benefit in AF since it only slows SA node)
- Positive inotropes (dobutamine, milrinone) = acute/bridge only - increase mortality if chronic
- Levosimendan = calcium sensitizer (does not increase Caยฒโบ, just makes troponin more sensitive to it)
Sources: Katzung's Basic and Clinical Pharmacology, 16th Edition; Goodman & Gilman's The Pharmacological Basis of Therapeutics; Braunwald's Heart Disease, 2-Volume Set